Literature DB >> 10170455

The economic potential of tamoxifen prophylaxis in breast cancer.

J R Butler1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 10170455     DOI： 10.2165/00019053-199712030-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  13 in total

Review 1.  Systemic therapy in breast cancer: efficacy and cost utility.

Authors:  J F Corry; P E Lønning
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

2.  Prevention of breast cancer with tamoxifen--an update on the Royal Marsden Hospital pilot programme.

Authors:  T J Powles; C R Tillyer; A L Jones; S E Ashley; J Treleaven; J B Davey; J A McKinna
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

Review 3.  Tamoxifen prophylaxis in breast cancer.

Authors:  R R Love
Journal:  Oncology (Williston Park)       Date:  1992-07       Impact factor: 2.990

4.  Symptoms associated with tamoxifen treatment in postmenopausal women.

Authors:  R R Love; L Cameron; B L Connell; H Leventhal
Journal:  Arch Intern Med       Date:  1991-09

Review 5.  Breast cancer chemoprevention. Tamoxifen: current issues and future prospective.

Authors:  R T Chlebowski; J Butler; A Nelson; L Lillington
Journal:  Cancer       Date:  1993-08-01       Impact factor: 6.860

Review 6.  Breast cancer chemoprevention.

Authors:  A Costa
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

Review 7.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1992-01-04       Impact factor: 79.321

8.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1992-01-11       Impact factor: 79.321

9.  Base-line quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial.

Authors:  P A Ganz; R Day; J E Ware; C Redmond; B Fisher
Journal:  J Natl Cancer Inst       Date:  1995-09-20       Impact factor: 13.506

10.  The decision to enter a randomized trial of tamoxifen for the prevention of breast cancer in healthy women: an analysis of the tradeoffs.

Authors:  R F Nease; J M Ross
Journal:  Am J Med       Date:  1995-08       Impact factor: 4.965
View more
  1 in total

Review 1.  Efficacy and economics of hormonal therapies for advanced breast cancer.

Authors:  Michael S Simon; Dina Ibrahim; Lisa Newman; Miron Stano
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.